Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Publication year range
1.
Internist (Berl) ; 46(10): 1152-7, 2005 Oct.
Article in German | MEDLINE | ID: mdl-16133219

ABSTRACT

A 71-year-old female, who has been treated with steroids for 3 weeks, developed a severe pneumonia with septic shock and acute respiratory distress syndrome (ARDS). Despite broad antibiosis due to the detection of pseudomonas aeruginosa (blood culture) the inflammatory markers remained high and the respiratory situation went critical. No proof of a malignoma or autoimmune process was found, despite multiple round foci in x-ray and computer tomography. Finally the delayed diagnosis of pulmonary nocardiosis was adjusted, due to the long incubation period of the pathogen Nocardia farcinica. The infectious origin may be assumed in so called "hay packs" used during the patient's residence at a health resort. After adequate change of the antibiotic regimen stabilization was achieved and the patient meanwhile recovered from the disease.


Subject(s)
Nocardia Infections/diagnosis , Pneumonia, Bacterial/diagnosis , Poaceae/adverse effects , Poaceae/microbiology , Pseudomonas Infections/diagnosis , Aged , Anti-Bacterial Agents/therapeutic use , Female , Humans , Nocardia Infections/drug therapy , Nocardia Infections/etiology , Pneumonia, Bacterial/drug therapy , Pneumonia, Bacterial/etiology , Pseudomonas Infections/drug therapy , Pseudomonas Infections/etiology , Rare Diseases/diagnosis , Rare Diseases/drug therapy , Rare Diseases/etiology
2.
Int J Cancer ; 80(4): 612-6, 1999 Feb 09.
Article in English | MEDLINE | ID: mdl-9935165

ABSTRACT

Bispecific antibodies (bsAbs) directed to tumor-associated antigens and to receptors mediating T-cell activation, such as the TCR/CD3 complex and the co-stimulatory CD28 molecule, are capable of activating T cells at the surface of tumor cells, resulting in tumor-cell killing. Here we report the pre-clinical characterization of bispecific-antibody fragments (bsFab2) directed to 2 different glioblastoma-associated antigens: the EGF receptor (EGFR) and a chondroitin-sulfate proteoglycan (CSPG). Using cultured glioblastoma cells expressing both target antigens, we found that the ability of anti-tumor x anti-CD28 bsFab2 to mediate "targeted T-cell co-stimulation" is superior for constructs targeting the CSPG molecule, correlating with an approximately 6-fold higher expression level of this antigen on the cell surface. In contrast, bsFab2 triggering CD3 are more effective if they contain EGFR-target specificity. This indicates that the activity of anti-tumor x anti-CD3 constructs critically depends on properties of the antigen other than its expression level on the cell surface, e.g., its mobility in the membrane. These findings prompted us to use EGFR-targeting bsFab2 in an ongoing clinical trial with glioma patients.


Subject(s)
Antibodies, Bispecific/therapeutic use , Antigens, Neoplasm/immunology , Immunoglobulin Fragments/therapeutic use , Immunotherapy , Lymphocyte Activation/immunology , T-Lymphocytes/immunology , Antibodies, Bispecific/immunology , Antigens, Neoplasm/metabolism , Antigens, Surface/immunology , CD28 Antigens/immunology , CD3 Complex/immunology , Chondroitin Sulfate Proteoglycans/immunology , ErbB Receptors/immunology , Glioblastoma/immunology , Glioblastoma/therapy , Humans , Immunoglobulin Fragments/immunology , Microscopy, Fluorescence , Tumor Cells, Cultured
3.
Transfusion ; 33(4): 311-5, 1993 Apr.
Article in English | MEDLINE | ID: mdl-8480351

ABSTRACT

During the last decade, the trend toward intensifying chemotherapeutic regimens in patients with hematologic malignancies rapidly increased the demand for single-donor platelet concentrates (PCs). The logistics of such supply, however, necessitated the storage of these blood components prior to transfusion. Today, most blood centers use di(2-ethylhexyl)phthalate-free blood bags, which are assumed to allow a storage period of up to 5 days. This report describes biochemical and functional changes of stored single-donor PCs, which may influence the expected quality of PCs. The acid-base status is characterized by an initial respiratory alkalosis compensated by a metabolic acidosis. Changes in extracellular electrolyte, lactate dehydrogenase, glucose, lactate, elastase, and complement levels, as well as in the release of alpha granule content and the initial activation of plasma coagulation, are demonstrated. These changes result in a functional impairment of stored PCs as reflected by thromboxane and serotonin release reaction and by aggregation and in vitro bleeding time studies. In contrast, in vivo recovery and survival rates have been reported to be unaffected. Whether the good recovery and survival rates are caused by a rejuvenescence of stored PCs in vivo or are due to injured circulating platelets has not yet been proven.


Subject(s)
Blood Donors , Blood Platelets , Blood Preservation , Adenosine Diphosphate/pharmacology , Blood Platelets/chemistry , Blood Platelets/metabolism , Blood Platelets/physiology , Blood Preservation/instrumentation , Blood Preservation/methods , Collagen/pharmacology , Diethylhexyl Phthalate/pharmacology , Homeostasis , Humans , Platelet Activation/physiology , Platelet Aggregation/physiology , Platelet Count , Platelet Factor 4/analysis , Serotonin/metabolism , Thromboxane B2/metabolism , Time Factors , beta-Thromboglobulin/analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...